• Biomm remains confident in its 2026 EBITDA guidance of R$ 90 million–R$ 100 million, potentially reaching the lower bound in November.
• October results slightly exceeded expectations, with public-sector insulin revenue reaching R$ 96.57 million versus R$ 5.87 million in October 2025.
• Combined September–October revenue exceeded first-half revenue by 16%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BIOMM SA published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.